ストックスクリーナーアプリを入手
6.00
3.99%
0.23
アフターアワーズ：
6.00
前日終値:
$5.77
開ける：
$5.69
24時間の取引高:
126.25K
Relative Volume:
1.82
時価総額：
$55.52M
収益：
-
当期純損益:
$-6.42M
株価収益率:
-1.0712
EPS:
-5.6013
ネットキャッシュフロー:
$-7.45M
1週間 パフォーマンス:
-14.16%
1か月 パフォーマンス:
-25.74%
6か月 パフォーマンス:
-33.18%
1年 パフォーマンス:
+170.27%
1日の値動き範囲:
$5.2801
$6.07
1週間の範囲:
$5.2801
$7.00
52週間の値動き範囲:
$1.92
$16.94
Cervomed Inc Stock (CRVO) Company Profile
CRVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
6.00 | 53.39M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-13 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-12-05 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-18 | 開始されました | Chardan Capital Markets | Buy |
| 2024-07-26 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-15 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cervomed Inc (CRVO) 最新ニュース
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is CervoMed Inc stock good for income investorsWeekly Trade Summary & Daily Stock Trend Reports - baoquankhu1.vn
Geopolitics Watch: Is CervoMed Inc stock a good pick for beginnersTrade Volume Report & Verified Chart Pattern Signals - baoquankhu1.vn
Market Overview: Does Coupang Inc have pricing powerChart Signals & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga
CervoMed (NASDAQ:CRVO) Upgraded at Zacks Research - Defense World
Growth Review: Can VSTEW sustain its profitabilityTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Ideas Watch: Is CervoMed Inc DP8 stock overpriced at current multiplesTrade Analysis Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
Will CervoMed Inc. stock see insider buying2025 Breakouts & Breakdowns & Smart Swing Trading Techniques - Улправда
Will CervoMed Inc. stock deliver consistent dividends2025 Risk Factors & Fast Gain Swing Alerts - Улправда
Is CervoMed Inc. (DP8) stock overpriced at current multiples2025 Year in Review & Daily Market Momentum Tracking - Улправда
CervoMed Releases Updated Investor Presentation and Business Overview - TipRanks
Is CervoMed Inc. stock a dividend growth opportunityWeekly Trade Review & Long-Term Growth Stock Strategies - Улправда
Will CervoMed Inc. stock gain from strong economyGlobal Markets & High Win Rate Trade Tips - Улправда
Aug Weekly: Is CervoMed Inc stock vulnerable to regulatory risksTrade Analysis Summary & Growth Focused Stock Pick Reports - Bộ Nội Vụ
Is CervoMed Inc DP8 a good long term investmentMarket Sentiment Report & Learn From the Strategies of Institutions - earlytimes.in
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Can CervoMed Inc. stock rebound after recent weakness2025 Market Overview & Risk Controlled Swing Alerts - Улправда
Will CervoMed Inc. (DP8) stock return to pre crash levels2025 Trading Volume Trends & Technical Pattern Based Signals - Улправда
What analyst consensus says on CervoMed Inc. stockStock Surge & Verified High Yield Trade Plans - Улправда
Is CervoMed Inc. stock vulnerable to regulatory risksEarnings Miss & Technical Analysis for Trade Confirmation - DonanımHaber
Aug Patterns: Will CervoMed Inc. stock gain from strong economyProduct Launch & AI Based Buy and Sell Signals - DonanımHaber
Why CervoMed Inc. (DP8) stock attracts wealthy investorsStop Loss & Advanced Technical Signal Analysis - DonanımHaber
CervoMed (NASDAQ:CRVO) Receives Buy Rating from HC Wainwright - Defense World
Can CervoMed Inc. stock sustain institutional interest2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Cantor Fitzgerald initiates CervoMed stock with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on CervoMed (CRVO) with Ove - GuruFocus
HC Wainwright Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - MarketBeat
Cantor Fitzgerald Initiates Coverage on CervoMed With Overweight Rating - marketscreener.com
Cantor Fitzgerald initiates CervoMed stock with Overweight rating - Investing.com India
CervoMed Earnings Notes - Trefis
CEO Change: Is CervoMed Inc DP8 stock supported by strong fundamentals2025 Trading Volume Trends & Technical Pattern Based Signals - moha.gov.vn
New Highs: Can CervoMed Inc. stock rebound after recent weaknessJuly 2025 Gainers & Precise Swing Trade Entry Alerts - moha.gov.vn
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock - Yahoo Finance
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-12-06 11:12:10 - moha.gov.vn
CervoMed Inc Announces New Data from RewinD-LB Trial - TradingView — Track All Markets
Today's Analyst Rating: CRVO Maintains "Buy" with $31 Price Targ - GuruFocus
Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsJuly 2025 Intraday Action & Daily Volume Surge Signals - Newser
What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - The Manila Times
Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser
Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus
CervoMed’s DLB drug shows promise in phase 2b trial By Investing.com - Investing.com Nigeria
CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com
CervoMed stock soars after promising dementia drug trial results By Investing.com - Investing.com South Africa
Cervomed Inc (CRVO) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):